Varsity Healthcare Partners (VHP), a lower middle-market healthcare services private equity firm, announced it has completed a strategic growth investment in Trialbee, a Sweden-headquartered, technology-enabled provider of patient recruitment services and analytics for clinical trials.
Trialbee works with global biopharma sponsors to help them meet enrollment timelines and patient diversity goals by combining data-driven targeting with omnichannel marketing and advertising across regions, channels, and patient populations. The company’s recruitment efforts are supported by its proprietary Honey platform, which Trialbee describes as a vendor-agnostic SaaS system that centralizes recruitment activities from interest through enrollment and provides real-time tracking, referral quality insights, and ROI reporting.
VHP said it will partner with Trialbee’s management team to support continued growth, including investments in commercial scale, technology innovation, and global delivery capabilities. Trialbee CEO Matt Walz will continue to lead the company with the existing senior leadership team. Piper Sandler advised VHP on the transaction, and financial terms were not disclosed.
KEY QUOTE:
“Trialbee has built a differentiated, technology-enabled platform that addresses a mission-critical need for biopharma sponsors, while building trust with both research sites and patients.”“Varsity, which brings deep healthcare services expertise and a proven track record of scaling founder- and management-led platforms, is an ideal partner for us during this next chapter as we continue to invest in our technology, expand our capabilities, and help more sponsors accelerate the development of life-changing therapies.”
Matt Walz, Chief Executive Officer, Trialbee
